Bukwang Withdraws Market Approval Request for Clevudine
Published: 2005-03-09 06:57:00
Updated: 2005-03-09 06:57:00
Bukwang Pharmaceutical announced on March 7th that it has made an autonomous withdrawal of its application submitted for a domestic market approval of anti-hepatitis B agent clevudine to the Korea Food and Drug Administration (KFDA).
According to the company, the decision to withdraw clevudine...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
